Madopar Depot

Levodopa/Benserazide, the active ingredient in Madopar Depot, is a dopa decarboxylase inhibitor combination presented as an oral formulation for oral use. It is indicated for the management of Parkinson's disease and Parkinsonian syndrome in adult patients, helping to restore deficient central dopamine levels and improve motor function.

GNH USA supplies Madopar Depot as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and serving hospitals, pharmacies and clinics worldwide through a regulated global distribution network, ensuring product integrity and timely delivery.

Madopar Depot is used within the dopaminergic therapy pathway to treat movement disorders associated with Parkinsonism. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates rigidity and gait disturbances caused by dopaminergic deficiency. - Levodopa‑responsive Parkinsonism: restores functional mobility in patients who respond to levodopa therapy.

Adverse reactions may occur with Madopar Depot and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially at higher doses. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe depression or suicidal thoughts: mood changes requiring immediate attention. - Cardiac arrhythmias: irregular heart rhythms that may be fatal.

When prescribing Madopar Depot, clinicians should consider several safety aspects. - Dose titration: start low and increase gradually to minimize dyskinesia. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - Psychiatric evaluation: assess for depression or hallucinations. - Renal/hepatic function: adjust if severe impairment is present. - Concomitant MAO‑B inhibitors: avoid unless specifically indicated. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Madopar Depot can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics with strong D2 antagonism: may diminish therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensives: may exacerbate orthostatic hypotension. - Iron or calcium supplements: reduce levodopa absorption if taken simultaneously. - SSRIs or SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.